Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent Exherin (ADH-1) administered once weekly in 3 week cycles by intravenous infusion in patients with N-cadherin expressing, incurable, solid tumors (Adherex protocol number AHX-01-004)

Trial Profile

Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent Exherin (ADH-1) administered once weekly in 3 week cycles by intravenous infusion in patients with N-cadherin expressing, incurable, solid tumors (Adherex protocol number AHX-01-004)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2010

At a glance

  • Drugs ADH 1 (Primary)
  • Indications Colorectal cancer; Gynaecological cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Dec 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 27 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2007 Added endpoints from media release 9088195
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top